Document Detail

The emerging role for type 5 phosphodiesterase inhibition in heart failure.
MedLine Citation:
PMID:  16914104     Owner:  NLM     Status:  MEDLINE    
Patients with heart failure (HF) due to left ventricular (LV) systolic dysfunction have abnormal endothelium-dependent, nitric oxide-cyclic guanosine monophosphate-mediated vasodilation in the pulmonary and skeletal muscle vasculature. Therefore, inhibition of type 5 phosphodiesterase (PDE5), the principle enzyme responsible for cyclic guanosine monophosphate catabolism in the lungs and skeletal muscle, has been targeted in an effort to counteract vasoconstriction that contributes to increased right and LV afterload in HF. The efficacy of PDE5 inhibition in the treatment of pulmonary arterial hypertension has led to the investigation of its potential utility in the treatment of HF patients with secondary pulmonary hypertension. Moreover, recent preclinical studies suggest direct myocardial effects of PDE5 inhibition that may counteract beta-adrenergic, hypertrophic, and pro-apoptotic signaling, three critical pathways in the development of LV dysfunction. This review outlines both the underlying rationale and the results of initial studies of the therapeutic effects of PDE5 inhibition in HF.
Gregory D Lewis; Marc J Semigran
Related Documents :
3988674 - Determinants of cardiac augmentation by elevations in intrathoracic pressure.
15637114 - Regional myocardial work by strain doppler echocardiography and lv pressure: a new meth...
20545994 - New, simple echocardiographic indexes for the estimation of filling pressure in patient...
7054574 - Left ventricular diastolic suction as a mechanism of ventricular filling.
16296704 - Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension...
8279374 - Circulatory and catecholamine changes during head-up tilt testing in neurocardiogenic (...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current heart failure reports     Volume:  3     ISSN:  1546-9530     ISO Abbreviation:  Curr Heart Fail Rep     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-17     Completed Date:  2006-12-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101196487     Medline TA:  Curr Heart Fail Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  123-8     Citation Subset:  IM    
Cardiology Division, Bigelow 800, MassachusettsGeneral Hospital, 55 Fruit St., Boston, MA 02114, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
Cyclic Nucleotide Phosphodiesterases, Type 5
Exercise Tolerance / drug effects
Heart / drug effects
Heart Failure / drug therapy*
Phosphodiesterase Inhibitors / pharmacology,  therapeutic use*
Piperazines / pharmacology,  therapeutic use
Vasodilation / drug effects
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 139755-83-2/sildenafil; EC',5'-Cyclic-GMP Phosphodiesterases; EC Nucleotide Phosphodiesterases, Type 5; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thyroid hormone and heart failure.
Next Document:  Management of acute pulmonary edema in the emergency department.